M&A Deal Summary

Takeda Pharmaceutical Acquires Envoy Therapeutics

On November 6, 2012, Takeda Pharmaceutical acquired life science company Envoy Therapeutics for 140M USD

Acquisition Highlights
  • This is Takeda Pharmaceutical’s 7th transaction in the Life Science sector.
  • This is Takeda Pharmaceutical’s 7th largest (disclosed) transaction.
  • This is Takeda Pharmaceutical’s 5th transaction in the United States.
  • This is Takeda Pharmaceutical’s 1st transaction in Florida.

M&A Deal Summary

Date 2012-11-06
Target Envoy Therapeutics
Sector Life Science
Buyer(s) Takeda Pharmaceutical
Deal Type Add-on Acquisition
Deal Value 140M USD

Target

Envoy Therapeutics

Jupiter, Florida, United States
website
Envoy Therapeutics, Inc. is a privately-held drug discovery company focused on finding new drugs with superior efficacy and fewer side effects than existing treatments.

Search 177,782 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Takeda Pharmaceutical

Tokyo, Japan

website


Category Company
Founded 1781
Sector Healthcare Services
Employees47,099
Revenue 3,197.8B JPY (2021)
DESCRIPTION

Takeda Pharmaceutical Co. is a Japan-based company engaged in the pharmaceutical business. Research & Development, Manufacturing, Sales and Marketing, and Import/Export of Pharmaceutical Drugs, etc.The Company operates in three business segments,Ethical, Healthcare and others. Takeda Pharmaceutical Company was founded in 1781 and is based in Tokyo, Japan.


DEAL STATS #
Overall 7 of 18
Sector (Life Science) 7 of 17
Type (Add-on Acquisition) 7 of 15
State (Florida) 1 of 1
Country (United States) 5 of 12
Year (2012) 2 of 2
Size (of disclosed) 7 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-10-04 LigoCyte Pharmaceuticals

Bozeman, Montana, United States

LigoCyte Pharmaceuticals is a privately-held biopharmaceutical company specializing in innovative vaccine products. Its lead product, a vaccine to prevent norovirus gastroenteritis, is in phase I/II of clinical development. LigoCyte Pharmaceuticals was founded in 1998 and is based in Bozeman, Montana.

Buy $60M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-05-08 Inviragen

Fort Collins, Colorado, United States

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide.

Buy $35M